Oricell Therapeutics Holdings Limited Secures $70 Million in Series C1 Financing to Advance Global Development of Innovative CAR-T Therapies

Global Innovative Tumor Immunotherapy Company "Oricell Therapeutics Holdings Limited" (referred to as “QrigincellTherapeutics” or “Oricell”) announced today the completion of a US$70 million Series C1 financing round. This round was led by Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund, with participation from QIA (Qatar Sovereign Fund), NGS (Australian pension fund), Yizhuang Guotou, Lich宸 Capital, Ruifeng Capital, and other institutions. Lightsource Capital, as a long-term partner of Oricell Therapeutics, has witnessed the company’s innovation and development in the biopharmaceutical field and sincerely takes pride in Oricell's progress. Moving forward, Lightsource will continue to provide professional support to help the company achieve further breakthroughs in the industry.

Qrigincell Therapeutics is a clinical-stage biotechnology company committed to becoming an innovation-driven global leader in the field of tumor immunotherapy. The company currently focuses on developing innovative cell therapies to address unmet medical needs in the global oncology and immunology fields. Leveraging proprietary expertise accumulated through its self-developed Ori®Ab antibody screening and engineering platform, Ori®Armoring structural platform, and OnGo(Fast)CMC, Qrigincell Therapeutics has developed multiple product pipelines for treating solid tumors and hematological malignancies. These products have demonstrated favorable safety and efficacy in exploratory clinical studies. Relevant clinical research data have been presented at international conferences such as the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, 2025 AACR, 2025 ASCO, and 2025 EHA, as well as in the international academic journal *The Lancet Haematology*. Qrigincell Therapeutics is dedicated to advancing the field of cell therapy through innovative technologies, bringing new hope to patients.